D-Wave Quantum: Record Order Book and Government Backing Face a Revenue Dip at London Conference

Quantum computing firm showcases real-world use cases at Qubits Europe 2026, balancing $33.4M quarterly orders with $2.9M revenue and $100M government grant tied to stock dilution.

D-Wave Quantum opens its flagship European conference in London today, a moment that shifts the spotlight from chart action to commercial reality. The stock, which has clawed back more than 86% from its March nadir, took a brief pause earlier this week, shedding roughly 3% on a weekly basis to close at €19.93. Yet that setback does little to obscure an underlying narrative that has grown far more complex: a company juggling a $33.4 million quarterly order haul, a $100 million government grant with dilution strings attached, and a revenue figure that has shrunk to $2.9 million from a prior-year spike.

The “Qubits Europe 2026: Quantum Realized” conference is designed to showcase real-world use cases, live demonstrations, and updates on D-Wave’s twin annealing and gate-model systems. With British royal endorsement — King Charles III cited quantum computing as a pillar of US-UK collaboration during his April address to Congress — London’s dense cluster of academics, startups, and corporate players provides a natural stage. For D-Wave, the event is a chance to convert European partnerships into tangible backlog, especially after the company disclosed at its June investor day that remaining performance obligations had swelled to over $42 million.

That pipeline is heavily weighted toward the near-term annealing business. In the first quarter, D-Wave booked orders worth $33.4 million, a nearly 20-fold jump from a year earlier. A single $20 million system sale to Florida Atlantic University and a $10 million service contract with a large US corporation accounted for the bulk. The catch: revenue came in at just $2.9 million, reflecting the lumpy nature of large-system sales and the time lag between booking and delivery. The year-ago quarter had been inflated by a one-time large sale, making the comparison unfavourable. The market now must decide whether the order backlog justifies a market capitalization of €7.46 billion.

D-Wave’s long-term ambition rests on a dual-platform strategy, unique among quantum hardware firms. Through its January acquisition of Quantum Circuits Inc., a Yale spinout, it now offers both annealing systems — already deployed in commercial applications — and gate-model computers based on fault-tolerant superconducting qubits. The roadmap calls for gate-model systems with 17, 49, and 181 physical qubits between 2026 and 2028, then moving to 10 logical qubits by 2030 and 100 by 2032, targeting quantum chemistry and AI workloads. The first gate-model delivery is expected later this year from D-Wave’s new research centre in New Haven.

The company also secured a non-binding memorandum of understanding for up to $100 million from the US CHIPS and Science Act, intended to support research sites in Florida, Connecticut, and Canada. The goal is an annealing system with 100,000 qubits and a gate-model system with 10,000 qubits. But the funding comes with clear caveats: D-Wave must issue $100 million in new shares to the Department of Commerce, and disbursements are tied to meeting milestones and congressional appropriations — nothing is guaranteed. The dilution risk is real, and investors are acutely aware that equity issuance could weigh on the stock even as the narrative of government validation shines.

Analysts remain uniformly bullish. All 13 covering the stock rate it a buy, with a consensus price target of $36.84 (approximately €31.45 at current rates) and a high of $45. That implies roughly 50% upside from Wednesday’s close. Yet the stock sits nearly 50% below its 52-week high of €38.48, and the 200-day moving average near €21 acts as a stubborn resistance level. The 140% annualized volatility is a constant reminder that sentiment in quantum stocks can flip with brutal speed.

D-Wave’s London conference is more than a marketing exercise. It is a test of whether the company can demonstrate that its record order book and government endorsement are translating into a sustainable commercial base — not just analyst optimism and a one-off university sale. The revenue gap may be uncomfortable, but the backlog is real. How European clients respond over the next few days will help determine whether the stock’s recent recovery has legs or is merely another quantum bounce.